DUBLIN--(BUSINESS WIRE)--Research and Markets has announced the addition of the "Fibrinogen Deficiency (Factor I Deficiency) - Pipeline Review, H1 2016" report to their offering.
This report provides comprehensive information on the therapeutic development for Fibrinogen Deficiency (Factor I Deficiency), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Fibrinogen Deficiency (Factor I Deficiency) and special features on late-stage and discontinued projects.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.
Key Topics Covered:
- Introduction
- Fibrinogen Deficiency (Factor I Deficiency) Overview
- Therapeutics Development
- Pipeline Products for Fibrinogen Deficiency (Factor I Deficiency) - Overview
- Pipeline Products for Fibrinogen Deficiency (Factor I Deficiency) - Comparative Analysis
- Fibrinogen Deficiency (Factor I Deficiency) - Therapeutics under Development by Companies
- Fibrinogen Deficiency (Factor I Deficiency) - Therapeutics under Investigation by Universities/Institutes
- Fibrinogen Deficiency (Factor I Deficiency) Products Glance
- Late Stage Products
- Clinical Stage Products
- Early Stage Products
- Fibrinogen Deficiency (Factor I Deficiency) - Products under Development by Companies
- Fibrinogen Deficiency (Factor I Deficiency) - Products under Investigation by Universities/Institutes
- Fibrinogen Deficiency (Factor I Deficiency) - Companies Involved in Therapeutics Development
- Biotest AG
- China Biologic Products, Inc.
- Grifols, S.A.
- LFB S.A.
- Octapharma AG
For more information visit http://www.researchandmarkets.com/research/jfbh33/fibrinogen
